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ABSTRACT 
 
Diabetes mellitus contributes for initiation and progression of micro vascular and 
macro vascular complications. Complication includes coagulation impairment 
however Shortened activated partial thromboplastin time (aPTT) values may reflect 
hypercoaguable state, which is associated with increased thrombotic risk and adverse 
cardiovascular events.  Objective: The present study was conducted to study the aPTT 
and PT levels in patients with diabetes mellitus type II. Material and method: A 
sample of 50 persons were selected, 30 patients suffering from DM as type II from Al-
wahda teaching hospital, Derna-Libya.  At the same time a group of 20 randomly 
selected healthy adults to participate in the study as control group. Result: The mean 
value of APTT in T2DM individuals was significant lower (28.95 ±7.54) seconds as 
compare with control, (34.12±2.82) seconds (P = 0.06).  The mean value of 
prothrombin time (PT) among T2DM individuals was (14.04 ±2.96) seconds and the 
mean value of PT among healthy individuals was (13.5 ± 1.54) seconds. There was no 
significant difference in PT of T2DM individuals P ≥ 0.05. Conclusion: From this study, 
it may be concluded that shorted APTT confirms that T2DM is a hyper-coagulable 
state due to which there is increased risk of thrombotic events 
 
KEYWORDS: Prothrombin time, Activated partial thromboplastin time, 
hypercoagulable, Diabetes mellitus. 
INTRODUCTION 
Diabetes mellitus (DM) is one of the most common serious 
metabolic disorders, it describes as metabolic disorder of 
multiple etiology characterized by chronic hyperglycemia 
with disturbance of carbohydrate, fat and protein 
metabolism resulting from defect in insulin secretion, action 
or both.[1] 
There are two general types of diabetes mellitus, type 1 
diabetes, also called insulin-dependent diabetes mellitus 
(IDDM), is caused by lack of insulin secretion and type 2 
diabetes (T2DM) also called non-insulin-dependent (NIDDM), 
is caused by decreased sensitivity of target tissues to the 
metabolic effect of insulin.[1] 80% of patients with diabetes 
mellitus die a thrombotic death, 75% of these deaths are due 
to Cerebrovascular and peripheral vascular complications.[2] 
It is well known that the vascular endothelium plays an 
essential role in the regulation of (local) haemostatic 
processes. Endothelial dysfunction has also been shown to 
occur in T2DM [2]. Multiple mechanisms are found to be 
involved in it; but most likely mechanism is that of the insulin 
resistance syndrome may be central to the development of 
diabetic endothelial dysfunction. 
The hemostatic abnormality and endothelial dysfunction are 
responsible for the generation of hyper-coagulable state in 
T2DM individuals [2]. Coagulation tests like prothrombin time 
(PT) and the activated partial thromboplastin time (APTT) are 
global tests used to assess the coagulation system in a clinical 
setting [3].  
Patients are considered to have a hypercoagulable state if 
they have laboratory abnormalities associated with increased 
risk of thrombosis. 
The aim was conducted to study the aPTT and PT levels in 
patients with diabetes mellitus type II T2DM. 
MATERIAL & METHOD  
Study Design: A case control comparative analytical study. 
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Ethical approval: Approval was granted from the Research 
and Ethics Committee of the faculty. Consent was gotten 
from all participated patients at Alwahda hospital. 
Sample size and sampling method: A sample of 50 person 
were selected, 30 patients suffering from DM   as type II , 
from Al-wahda teaching hospital, Derna-Libya.  At the same 
time a group of 20 randomly selected healthy adults were 
invited to participate in the study as control group. 
Inclusion criteria 
1. T2DM individuals of either sex between the age group of 
31 to 72 years. For this study, diabetic individuals who 
attended to alwahda hospital at medicine department; and 
were diagnosed previously as T2DM were selected. 
Diagnostic criteria for DM issued by the National Diabetes 
Data Group and WHO was applied as: [1] 
1) Symptom of diabetes plus random blood glucose> 
200mg% OR 
 2) Fasting plasma glucose >126mg% OR 
3) Two hour plasma glucose >200mg% during oral glucose 
tolerance test 
All individuals were maintained on anti-diabetic treatment 
like oral hypoglycaemic 
2. Healthy individuals of either sex between the age group of 
21 to 50 years. 
Exclusion criteria: 
1. H/o clinical conditions associated with increased risk of 
thromboembolic diseases, like venous thrombosis, 
cerebrovascular diseases, peripheral vascular diseases. 
2. Past H/o predisposition to hyper-coagulability like known 
inherited coagulative disorders, cancer, recent surgery, 
pregnancy, hyperthyroidism etc. 
3. H/o heart diseases like myocardial infarction, 
hypertension, angina pectoris, positive electrocardiographic 
changes etc. 
Grouping:  
Group I: It consisted of 20, healthy individuals. 
Group II: This group consisted of 30, T2DM individuals.  
Sample collection:  
Five ml of venous blood specimen were collected from all 
patients and control in medical laboratory at Alwahda- 
hospital, plasma was separated for testing prothrombin time 
and activated partial thromboplastin time. 
Methodology: 
Study Procedure: 
The objective and detailed procedure were explained to each 
individual, before collection of the blood sample following 
coagulation parameters were studied, 
a) Prothrombin time (PT) 
b) Activated partial thromboplastin time (APTT) 
 
Procedure for coagulation tests:  Collected samples from both 
the patients and controls in clean container or a tube having 
3.2% trisodium citrate. 
 Immediately mixed the blood with anticoagulant 
avoiding foam formation. Centrifuge the sample for 15 
min at approximately 3000 rpm and collect the plasma in 
separate tube. 
 Fresh plasma is preferred for testing as it performs best 
when tested immediately. 
 Sample may be tested within 2 hours at 25 to 30° C and 
within 3 hours at 2 to 8° C. 
 Take haemostatic reagent into a test tube; add patient 
plasma into test tube or reaction cuvette. 
 Incubate the test tube containing plasma and reagent, PT 
and APTT were measured on coagulometer model.[4]  
 Our laboratory reference ranges of coagulation tests 
were; PT (11-14 seconds) and APTT (30 seconds). 
Statistical analysis:  Data were analyzed by t test using. 
Results are expressed as mean values ± SD. Significant 
difference was considered to exist at P value less than 0.05. 
RESULTS 
A total of 50 sample were included in this study, 20 normal 
healthy persons were included in the study as control subject 
mean age (24.06 ±3.73) with a range 20-33 year  and they 
were clinically healthy and free of any serious illness. 
Thirty patient as T2DM were selected from Al-wahda 
Teaching Hospital, Derna, ge mean age ( 51.13 ± 11.52) with  
a range ( 35- 65 ) year.  
The mean value of APTT in T2DM individuals was 28.95 
seconds with standard deviation ±7.54 seconds while mean 
value with standard deviation in healthy individuals was 
34.12±2.82 seconds. 
By applying unpaired t test, we found that, there were 
significantly decreased value of APTT among T2DM 
individuals than healthy individuals (p =006) as in table 1. 
The mean value of prothrombin time (PT) among T2DM 
individuals was 14.04 seconds with standard deviation ±2.96 
seconds and the mean value of PT among healthy individuals 
was 13.5 seconds with standard deviation ± 1.54 seconds. 
By applying unpaired t test, we found no significant 
difference in PT of T2DM individuals P ≥ 0.05 as in table 2. 
 
Table 1: Comparison of APTT, PT between Group I (healthy 
individuals) and Group II T2DM 
 Group I Group II P value 
Activated partial 
thromboplastin 
time (in second) 
34.12±2.82 28.95±7.54 0.006* 
Prothrombin time 
(in second) 
13.5±1.54 14.04±2.96 0.25 
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DISCUSSION  
Diabetes mellitus is associated with increased risk of 
atherosclerosis, so diabetes is a pro coagulant state. DM is 
characterized by high risk of atherothrombotic complications 
affecting the coronary, cerebral and peripheral arterial trees. 
It is a syndrome characterized by presence of chronic 
hyperglycaemia due to defective insulin secretion, insulin 
action or both affecting metabolism of various compounds 
including carbohydrate, lipids, and proteins and it also 
impairs various biological processes such as coagulation and 
fibrinolytic alteration. 
Therefore in the present study we evaluated some of 
coagulation tests in T2DM individuals. 
The mean value of APTT in T2DM was 28.95 seconds while in 
healthy individuals it was 34.12 seconds. We found 
statistically significant difference in p value as 0.006, which 
shows that, T2DM is associated with shorter APTT. Our 
results are supported by similar findings of Zhao et al [ 5] and 
Chan et al.[ 6] Their results also showed that DM is associated 
with shortened activated partial thromboplastin time. In 
contrast, Abdulraheman & Dallatu [7] and Alao et al.[ 8] found 
increased APTT in their study results. 
The mean value of PT in T2DM was 14.04 seconds and in 
healthy individual it was 13.5 seconds. no significant 
difference in PT was found in the T2DM and healthy 
individuals. Similar findings were observed in Soltani et al. [9] 
and Madan et al. [10] studies in which they had reported 
normal PT in T2DM individuals. While Zhao et al. [11] and 
Acang & Jalil [12] found shorter PT in T2DM individuals. Raised 
PT in T2DM individuals was found by Hassan [13] and There 
are various factors that promote the coagulation while others 
inhibit coagulation, whenever there is imbalance between 
these two factors, blood will coagulate. Enhanced activation 
of clotting system has been implicated as contributing factor 
for the occurrence of vascular complications. The 
endothelium contributes for maintaining the blood flow by 
preventing platelet aggregation, by its anticoagulant 
properties and by stimulating the fibrinolytic system. The 
endothelium consists of a single layer of cells lining the inside 
surface of blood vessels, hence establishing a barrier 
between the blood and the vessel. [14] 
The most important factors for preventing clotting in the 
normal vascular system are the 
smoothness of the endothelial cell surface, which prevents 
contact activation of the intrinsic clotting system; a layer of 
glcocalyx on the endothelium (glycocalyx is a 
mucopolysaccharide adsorbed to the surfaces of the 
endothelial cells), which repels clotting factors and platelets, 
thereby preventing activation of clotting and a protein bound 
with the endothelial membrane, thrombomodulin which 
binds thrombin. [15] 
Endothelial dysfunction is the earliest event that precedes 
the development and progression of diabetic vascular 
complications. The pathogenesis of endothelial dysfunction 
in diabetes is complex. Multiple cellular and molecular 
mechanisms are involved in the development of diabetic 
dysfunctional endothelium. Along with hyperglycemia insulin 
resistance, impaired lipid metabolism and lipoproteins, 
oxidative stress, all these factors lead to endothelial 
dysfunction in T2DM.  
The APTT assay is traditionally used for identifying 
abnormalities in the contact (factor XII, prekallikrein, and 
high-molecular-weight kininogen), intrinsic (factors XI, VIII, 
IX) and common (factors X, V and II and fibrinogen) pathways 
of coagulation. Hence there was shortened APTT in T2DM. [17] 
The laboratory result of shorted APTT confirms that T2DM is 
a hyper-coagulable state due to which there is increased risk 
of thrombotic events. Clinical tests for APTT relatively 
inexpensive and are readily available. The results shown in 
our study indicated that shortened APTT levels might be 
useful haemostatic markers in diabetic patients, especially in 
those at high-risk for thrombotic complications. 
CONCLUSION  
APTT in which used for identify abnormalities in intrinsic and 
common coagulation pathway was shorter in T2DM than 
healthy individuals, shorted APTT confirm that T2DM is a 
hyper-coagulable state which increases risk of thrombotic 
events. 
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